ICLR ICON Public Limited Company
USHealthcareAs of 2026-07-09 16:00
Why ICLR matters now
ICON Public Limited Company (ICLR) is a US stock in Healthcare. The latest InvestLog snapshot shows $168.77 with +1.99% on the session and $12.92B in market capitalization; recent performance reads 1-month +28.58% and YTD -19.88%.
The latest financial table shown here is Q4 2025, with revenue of $2.11B, net income of $149.2M, and EPS of $1.93. Investors can compare that operating picture with valuation signals such as P/E 13.61 and FCF yield 12.0%.
The latest indexable market news headline is "INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $135.50; recent insider activity includes Elliott Jeffrey Thomas filing ; recent congressional disclosure data includes Kevin Hern Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
13.61
PEG
—
P/B
1.25
P/S
1.37
EV/EBITDA
10.84
DCF Value
$200.29
FCF Yield
12.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
25.2%
Operating Margin
11.0%
Net Margin
6.0%
ROE
5.2%
ROA
3.0%
ROIC
6.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.11B | $149.2M | $1.93 |
| FY 2025 | $8.25B | $229.3M | $2.90 |
| Q3 2025 | $2.04B | $2.4M | $0.03 |
| Q2 2025 | $2.02B | $183.0M | $2.30 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$139.90
Target (Median)
$135.50
Target Range
$100.00 - $216.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
IE
Exchange
—
Beta
1.27
ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. The firm excels in the strategic design, execution, and analytical oversight of programs that facilitate the entire spectrum of clinical trials, from initial compound identification through all phases (I-IV) of human studies. Its comprehensive suite of clinical development offerings encompasses early-stage drug development, strategies for patient enrollment and retention, strategic planning and data analysis, late-phase investigations, cutting-edge data and technology platforms, and expert consulting. Additionally, ICON provides specialized medical imaging, clinical research, and laboratory services; meticulous project management; efficient site monitoring and administration; robust data management; biostatistical analysis and programming; professional medical writing and publication support; medical affairs expertise; independent endpoint adjudication and data monitoring committee services; vigilant pharmacovigilance; interactive response technologies (IRT); streamlined clinical supplies logistics; strategic regulatory guidance; impactful medical communication; and broad advisory services. ICON's diverse clientele includes companies across the pharmaceutical, biotechnology, and medical device sectors, alongside governmental and public health bodies. Established in 1990, the company maintains its headquarters in Dublin, Ireland.